In cell line models of MLL-rearranged ALL, DOT1L inhibitors have been shown to inhibit the aberrant gene expression pattern associated with DOT1L activity and to potently induce cell death[41]. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.